Bacher, Ulrike

[["dc.bibliographiccitation.firstpage","146"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Acta Haematologica"],["dc.bibliographiccitation.lastpage","154"],["dc.bibliographiccitation.volume","134"],["dc.contributor.author","Mendorf, Alexander"],["dc.contributor.author","Klyuchnikov, Evgeny"],["dc.contributor.author","Langebrake, Claudia"],["dc.contributor.author","Rohde, Holger"],["dc.contributor.author","Ayuk, Francis"],["dc.contributor.author","Regier, Marc"],["dc.contributor.author","Christopeit, Maximilian"],["dc.contributor.author","Zabelina, Tatjana"],["dc.contributor.author","Bacher, Adelbert"],["dc.contributor.author","Wolschke, Christine"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Stübig, Thomas"],["dc.date.accessioned","2018-11-07T10:02:55Z"],["dc.date.available","2018-11-07T10:02:55Z"],["dc.date.issued","2015"],["dc.description.abstract","Toxoplasmosis and infections by other opportunistic agents such as Pneumocystis jirovecii constitute life-threatening risks for patients after allogeneic hematopoietic stem cell transplantation. Trimethoprim/sulfamethoxazole (TMP-SMX) has been well established for post-transplant toxoplasmosis and pneumocystis prophylaxis, but treatment may be limited due to toxicity. We explored atovaquone as an alternative and compared it with TMP-SMX regarding toxicity and efficacy during the first 100 days after transplantation in 155 consecutive adult stem cell recipients. Eight patients with a prior history of TMP-SMX intolerance received atovaquone as first-line prophylaxis. TMP-SMX was used for 141 patients as first-line strategy, but 13 patients (9.2%) were later switched to atovaquone due to TMP-SMX toxicity or gastrointestinal symptoms. No active toxoplasmosis or active P. jirovecii infection developed under continued prophylaxis with either TMP-SMX or atovaquone. However, for reasons of TMP-SMX and/or atovaquone toxicity, 7 patients were unable to tolerate any efficacious toxoplasmosis prophylaxis and therefore obtained inhalative pentamidine as P. jirovecii prophylaxis but no toxoplasmosis prophylaxis. Importantly, 2 of these patients developed severe toxoplasmosis. In summary, atovaquone appears as a valid alternative for at least some post-transplant patients who cannot tolerate TMP-SMX. This should be further confirmed by multicenter trials. (C) 2015 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000380757"],["dc.identifier.isi","000361636000003"],["dc.identifier.pmid","25968483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38332"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9662"],["dc.relation.issn","1421-9662"],["dc.relation.issn","0001-5792"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]